Document is current
Any future updates will be listed below
-
Authors
Nestor, John J.
Parkes, David
Feigh, Michael
Suschak, John J.
Harris, M. Scott
-
Funding
Funding for this research was provided by:
Spitfire Pharma Inc
- License Information
-
More Information
Article History
Received: 10 October 2021
Accepted: 8 April 2022
First Online: 23 April 2022
Competing interests
: J.J.N. is a consultant to Altimmune, Inc., holds a financial interest in the company, and holds patents on ALT-801 and the EuPort™ technology used for peptide prolongation. D.P. is a consultant to Altimmune, Inc. M.F. is an employee of Gubra Aps, which conducted the trial. J.J.S. and M.S.H. are employees of Altimmune, Inc. and hold a financial interest in the company.
